Moreover, neutralizing activity at visit four was significantly lower in patients with IBD treated with anti-TNFα compared to both non-anti-TNFα-treated patients and HCs (p = 0.0077 and p = 0.016, respectively), and the visit four/visit three ratio was significantly lower in the anti-TNFα group compared to HCs (p < 0.05; Figure 3B). This evidence concerns the gene TNF and inflammatory bowel disease.